Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Telaprevir

FDA-approved product (tablet, oral), marketed as Incivek.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Telaprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Telaprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Telaprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Antiviral Therapy on Gastroesophageal Varices.

    NCT02758509 · start 2010-01-01

    Registered record
    Registry ID
    NCT02758509
    Conditions
    Chronic Hepatitis C; Cirrhosis
    Interventions
    Pegylated interferon alfa-2a + Ribavirin; Pegylated interferon alfa-2a + Ribavirin + Boceprevir; Pegylated interferon alfa-2a + Ribavirin +Telaprevir; Ledipasvir/Sofosbuvir; Ombitasvir/paritaprevir/ritonavir+Dasabuvir; Daclatasvir+Sofosbuvir; Simeprevir+Sofosbuvir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-01-01
    Completion
    2017-10-15
    Enrolment
    237

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Cirrhosis
    InterventionPegylated interferon alfa-2a + Ribavirin; Pegylated interferon alfa-2a + Ribavirin + Boceprevir; Pegylated interferon alfa-2a + Ribavirin +Telaprevir; Ledipasvir/Sofosbuvir +3 more
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

    NCT01038167 · start 2010-01

    Registered record
    Registry ID
    NCT01038167
    Conditions
    Hepatitis C
    Interventions
    telaprevir; telaprevir; cyclosporine; cyclosporine; tacrolimus; tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    Interventiontelaprevir; telaprevir; cyclosporine; cyclosporine +2 more
    PhasePhase 1
    Registry statusCompleted

  • VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

    NCT00973388 · start 2009-10

    Registered record
    Registry ID
    NCT00973388
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-10
    Completion
    2010-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Moxifloxacin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

    NCT00983853 · start 2009-10

    Registered record
    Registry ID
    NCT00983853
    Conditions
    Hepatitis C; HIV Infections
    Interventions
    telaprevir or matching placebo; telaprevir or matching placebo; peginterferon alfa-2a; ribavirin (fixed dose); ribavirin (weight-based dose)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    Not recorded
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HIV Infections
    Interventiontelaprevir or matching placebo; telaprevir or matching placebo; peginterferon alfa-2a; ribavirin (fixed dose) +1 more
    PhasePhase 2
    Registry statusCompleted

  • Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

    NCT00958152 · start 2009-08

    Registered record
    Registry ID
    NCT00958152
    Conditions
    Hepatitis C
    Interventions
    VCH-222; VCH-222; VCH-222; telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    2010-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionVCH-222; VCH-222; VCH-222; telaprevir
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

    NCT00933283 · start 2009-07

    Registered record
    Registry ID
    NCT00933283
    Conditions
    Healthy Participants
    Interventions
    Telaprevir; Methadone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-07
    Completion
    2009-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionTelaprevir; Methadone
    PhasePhase 1
    Registry statusCompleted

  • Virology Follow up Study in Subjects Previously Treated With Telaprevir

    NCT00916474 · start 2009-06

    Registered record
    Registry ID
    NCT00916474
    Conditions
    Hepatitis C
    Interventions
    telaprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-06
    Completion
    2013-12
    Enrolment
    408

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    Interventiontelaprevir
    PhaseNot recorded
    Registry statusCompleted

  • VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer

    NCT00828789 · start 2009-02

    Registered record
    Registry ID
    NCT00828789
    Conditions
    Hepatitis C; HCV; HIV; AIDS
    Interventions
    Efavirenz; Tenofovir disoproxil fumarate; Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2009-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HCV; HIV; AIDS
    InterventionEfavirenz; Tenofovir disoproxil fumarate; Telaprevir
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

    NCT00781274 · start 2008-12

    Registered record
    Registry ID
    NCT00781274
    Conditions
    Hepatitis C
    Interventions
    MP-424; Ribavirin; Peginterferon Alfa-2b
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    2010-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionMP-424; Ribavirin; Peginterferon Alfa-2b
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

    NCT00780910 · start 2008-11

    Registered record
    Registry ID
    NCT00780910
    Conditions
    Chronic Hepatitis C
    Interventions
    MP-424; Ribavirin; Peginterferon Alfa-2b
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2010-10
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionMP-424; Ribavirin; Peginterferon Alfa-2b
    PhasePhase 3
    Registry statusCompleted

  • A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

    NCT00703118 · start 2008-10

    Registered record
    Registry ID
    NCT00703118
    Conditions
    Hepatitis C, Chronic
    Interventions
    Telaprevir; Peg-IFN-alfa-2a; Ribavirin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-10
    Completion
    2010-07
    Enrolment
    663

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionTelaprevir; Peg-IFN-alfa-2a; Ribavirin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

    NCT00630058 · start 2008-04

    Registered record
    Registry ID
    NCT00630058
    Conditions
    Hepatitis C
    Interventions
    MP-424(H), PEG-IFN-a-2b, RBV; MP-424 (L), PEG-IFN-a-2b, RBV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-04
    Completion
    2009-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionMP-424(H), PEG-IFN-a-2b, RBV; MP-424 (L), PEG-IFN-a-2b, RBV
    PhasePhase 1
    Registry statusCompleted

  • An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

    NCT00580801 · start 2008-01

    Registered record
    Registry ID
    NCT00580801
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Pegylated-interferon-alfa-2a; Placebo; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Pegylated-interferon-alfa-2a; Placebo; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

    NCT00621296 · start 2008-01

    Registered record
    Registry ID
    NCT00621296
    Conditions
    Hepatitis C
    Interventions
    MP-424 (Telaprevir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-02
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionMP-424 (Telaprevir)
    PhasePhase 2
    Registry statusCompleted

  • Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

    NCT00591214 · start 2007-12

    Registered record
    Registry ID
    NCT00591214
    Conditions
    Chronic Hepatitis C
    Interventions
    MP-424 (Telaprevir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionMP-424 (Telaprevir)
    PhasePhase 1
    Registry statusCompleted